People: Acceleron Pharma Inc (XLRN.O)
20 Jan 2017
Dr. Matthew L. Sherman, M.D., is Executive Vice President and Chief Medical Officer of the Company. He joined Acceleron in May 2006. Previously, he served as Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals Corp. where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs, quality assurance and program management. Prior to that, Dr. Sherman worked at Genetics Institute and Wyeth Pharmaceuticals in various capacities including Therapeutic Area Director for Oncology. While at Wyeth, Dr. Sherman provided senior oncology and hematology leadership for worldwide clinical development for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg® by the FDA. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Sherman received an SB in chemistry from the Massachusetts Institute of Technology and an MD from Dartmouth Medical School.
|Total Annual Compensation, USD||413,033|
|Restricted Stock Awards, USD||1,430,140|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||1,573,990|
|Fiscal Year Total, USD||3,417,170|